News Releases

MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million GAITHERSBURG, Md., May 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling

RNS Number : 1970K MaxCyte, Inc. 04 May 2022   MaxCyte to Participate in Upcoming Investor Conferences GAITHERSBURG, MD , May 4, 2022   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance

GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,

RNS Number : 9260J MaxCyte, Inc. 29 April 2022     MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights   Gaithersburg, Maryland - 29 April 2022 :       MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance

GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,

RNS Number : 5031I MaxCyte, Inc. 19 April 2022   MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, MD , April 19, 2022   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform

GAITHERSBURG, Md., April 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,

RNS Number : 1844I MaxCyte, Inc. 13 April 2022   MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue   GAITHERSBURG, MD , April 13, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering

GAITHERSBURG, Md., April 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,

RNS Number : 8763H MaxCyte, Inc. 11 April 2022   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing